Aktienanalyse zu Repligen Corp (RGEN)RGENRepligen Corp

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its franchises include filtration, chromatography, process analytics and proteins. Its filtration franchise includes product offering covering upstream and downstream technologies. Its filtration products include XCell Alternating Tangential Flow (ATF) Cell Retention Systems, Flat Sheet Cassettes, Hollow Fiber Consumables, Tangential Flow Filtration Systems and Fluid Management. Its chromatography franchise includes products used in downstream purification, development, manufacturing and quality control of biological drugs. Its chromatography franchise includes OPUS Pre-Packed Columns, KRM Chromatography Systems and other additional chromatography products. Its process analytics include Downstream process analytical technology (PAT) and Upstream PAT. Its Proteins include Protein A Affinity Ligands, AVIPure Resins for New Modalities and Growth Factors. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Repligen Corp (RGEN) is currently priced at $175.42, which is below the average analyst price target of $225, indicating potential upside. However, the RSI is at 46.469, suggesting the stock is neither overbought nor oversold, indicating a neutral momentum. The forward P/E ratio is 67.11, which is relatively high, indicating that the stock may be overvalued compared to its earnings potential. The main risk is the recent negative price movement, with a 4.75% drop yesterday, which could indicate bearish sentiment in the short term.

6 analysts cover RGEN: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 189.00.